BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, February 1, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

July 12, 2000

View Archived Issues

Company Profile: ProlX Pharmaceuticals

Read More

Millennium to acquire Cambridge Discovery Chemistry

Read More

Pharmacokinetics and pharmacodynamics of selective ETA antagonist examined in humans

Read More

Schering-Plough enters asthma collaboration with Texas Biotechnology

Read More

Methods of differentiating response to INN-00835 and placebo described at CINP congress

Read More

Propranolol may improve disruptive agitation in AD without serious cardiovascular effects

Read More

Cymserine and analogues, potent and selective BChE inhibitors with potential in AD

Read More

Neotrofin as a novel approach to AD discussed at World Alzheimer Congress

Read More

Virax and IDT receive funding from U.S. NIH to develop HIV vaccines

Read More

NIH accelerates development of HIV vaccines

Read More

[18F]-L-829165: a promising PET tracer for the brain NK1 receptor

Read More

AlphaOne enters agreement with Dana-Farber for tumor suppressor gene

Read More

Biological characteristics of A-176120, a potent FPP mimetic with promise as a cancer therapeutic

Read More

Antisense collaboration established by Lorus Therapeutics and AVI BioPharma

Read More

PathoGenesis commences phase I trial of AeroDose TOBI

Read More

Murine and humanized monoclonal antibodies against alphav integrin receptors

Read More

Synthesis, activity and use of new gabapentin-related compounds

Read More

Novo Nordisk presents new heterocyclic inhibitors of factor VIIa-TF activity

Read More

New Yissum compounds useful against oxidative stress or free radical injury

Read More

Tetracycline derivatives with broad indications reported by CollaGenex

Read More

Novel cathepsin K inhibitors and their use in bone disorders patented

Read More

Broad-spectrum antibacterial compounds emerge from Daiichi R&D

Read More

UT researchers patent dibenzofluorene derivatives with cytotoxic activity

Read More

New series under development at Glaxo Wellcome inhibits hepatic ApoB-100 production

Read More

T-20 phase II results highlighted at AIDS Conference

Read More

Genta begins follow-up studies of Genasense combination therapy for prostate cancer

Read More

CV Therapeutics and Fujisawa form CVT-3146 collaboration

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    Briefs
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing